Trials / Terminated
TerminatedNCT01927757
Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab
A Single Arm Trial to Evaluate the Efficacy of Etanercept in Moderate to Severe Rheumatoid Arthritis Patients Who Failed to Respond or Lost a Satisfactory Response to Treatment With Adalimumab When Used as Their First Biologic Agent
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of etanercept in adults with moderate-to-severe rheumatoid arthritis (RA) who did not respond to or lost a satisfactory response to adalimumab when used as their first biologic agent.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Etanercept | Administered by subcutaneous injection |
| DRUG | Methotrexate | Background methotrexate at least 15 mg weekly |
Timeline
- Start date
- 2013-05-06
- Primary completion
- 2015-06-11
- Completion
- 2015-06-11
- First posted
- 2013-08-23
- Last updated
- 2018-01-30
- Results posted
- 2016-07-11
Locations
45 sites across 3 countries: United States, Canada, Puerto Rico
Source: ClinicalTrials.gov record NCT01927757. Inclusion in this directory is not an endorsement.